Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized phase 2 study of concizumab prophylaxis in adults with hemophilia A or B with inhibitors
MOH_2017-06-22_000473Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of concizumab in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Efficacy of concizumab prophylaxis in preventing bleeding episodes and Safety of concizumab prophylaxis. Started Jun 2017; status: completed.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on MOH_2017-06-22_000473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-22_000473.